Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Eric Orlemans"'
Autor:
Timothy L. Chen, Bonnie Harrington, Jean Truxall, Ronni Wasmuth, Alexander Prouty, Shelby Sloan, Amy M. Lehman, Deepa Sampath, Eric Orlemans, Robert A. Baiocchi, Lapo Alinari, John C. Byrd, Jennifer A. Woyach, Erin Hertlein
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Abstract B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse
Externí odkaz:
https://doaj.org/article/4c01d238e7a84a94ba1ec2e43998f4b6
Autor:
Alexander Prouty, Jennifer A. Woyach, Amy Lehman, Bonnie K. Harrington, Ronni Wasmuth, Eric Orlemans, Erin Hertlein, Timothy L. Chen, Jean Truxall, Deepa Sampath, Robert A. Baiocchi, Shelby Sloan, Lapo Alinari, John C. Byrd
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse on ibrut
Autor:
Ronni Wasmuth, Eric Orlemans, Timothy L. Chen, Bonnie K. Harrington, Erin Hertlein, Amy Lehman, Jean Truxall, Jennifer A. Woyach, John C. Byrd
Publikováno v:
Cancer Research. 78:1964-1964
While chronic lymphocytic leukemia (CLL) is effectively treated by the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, patients that do relapse on ibrutinib (approximately 19%) have an extremely poor clinical outcome without further intervention.
Publikováno v:
American Journal of Gastroenterology. 104:S514-S515
Publikováno v:
American Journal of Gastroenterology. 103:S487-S488
Publikováno v:
Gastroenterology. 136:A-611
Publikováno v:
Gastroenterology. 136:A-612